Dipeptidyl peptidase-4 inhibition ameliorates western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function

Diabetes

Volumn 64, Issue 6, 2015, Pages 1988-2001

  Aroor, Annayya R ^a   Habibi, Javad ^a   Ford, David A ^b,c   Nistala, Ravi ^a   Lastra, Guido ^a   Manrique, Camila ^a   Dunham, Merlow M ^b,c   Ford, Kaitlin D ^b,c   Thyfault, John P ^a,d,e   Parks, Elizabeth J ^a,d,e   Sowers, James R ^a,d,e   Rector, R Scott ^a,d,e  

^a UNIVERSITY OF MISSOURI   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d University of Missouri   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CERAMIDE; CHOLESTEROL; DIACYLGLYCEROL; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MK 0626; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; SIRTUIN 1; SIRTUIN 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; MK0626; PALMITIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CITRIC ACID CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; FATTY LIVER; GLUCONEOGENESIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID DIET; LIPID LIVER LEVEL; LIVER MITOCHONDRION; LIVER WEIGHT; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY COMPOSITION; C57BL MOUSE; DRUG EFFECTS; LIVER; METABOLISM; MITOCHONDRION; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BODY COMPOSITION; CERAMIDES; DIET, WESTERN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY LIVER; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; MITOCHONDRIA; PALMITATES; PYRUVIC ACID; TRIAZOLES; TRIGLYCERIDES;

EID: 84944393898     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0804     Document Type: Article

References (59)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
2. Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011;1:5-12.
3. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 2014;18:91-112.
4. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013;62:3307-3315.
5. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013;57:2525-2531.
6. Bray GA. Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep 2012;14:570-578.
7. Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 2013;14:22933-22966.
8. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.
9. Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non- Alcoholic fatty liver disease: A novel liver disease biomarker. PLoS One 2010;5:e12226.
10. Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 2013;13:307-318.
11. Samson SL, Bajaj M. Potential of incretin-based therapies for non- Alcoholic fatty liver disease. J Diabetes Complications 2013;27:401-406.
12. Kern M, Klöting N, Niessen HG, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012;7:e38744.
13. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011;60:1246-1257.
14. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852-871.
15. Rector RS, Thyfault JP, Uptergrove GM, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non- Alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010;52:727-736.
16. Longato L. Non- Alcoholic fatty liver disease (NAFLD): A tale of fat and sugar? Fibrogenesis Tissue Repair 2013;6:14.
17. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011;108: 16381-16385.
18. Gorden DL, Ivanova PT, Myers DS, et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One 2011;6:e22775.
19. Rector RS, Morris EM, Ridenhour S, et al. Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepatology 2013;57:2213-2223.
20. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-810.
21. Edmondson SD, Mastracchio A, Mathvink RJ, et al. (2S, 3S)-3-Amino-4-(3, 3- difluoropyrrolidin-1-yl)-N, N-dimethyl-4-oxo-2-(4-[1, 2, 4]triazolo[1, 5- A]-pyridin-6- ylphenyl)butanamide: A selective alpha- Amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2006;49:3614-3627.
22. Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 2014;155:2266-2276.
23. Bostik B Habibi J, Ma L, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism 2014;63:1000-1011.
24. Li Y, Xiao J, Tian H, et al. The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice. Peptides 2013;49:91-99.
25. Demarco VG, Ford DA, Henriksen EJ, et al. Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology 2013;154:159-171.
26. Han X, Gross RW. Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem 2001;295:88-100.
27. Fletcher JA, Meers GM, Linden MA, et al. Impact of various exercise modalities on hepatic mitochondrial function. Med Sci Sports Exerc 2014;46:1089- 1097.
28. Noland RC, Koves TR, Seiler SE, et al. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 2009;284:22840-22852.
29. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res 2005;46:2023-2028.
30. Berglund ED, Li CY, Poffenberger G, et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 2008;57:1790-1799.
31. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55:390-397.
32. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181.
33. Parlevliet ET, Wang Y, Geerling JJ, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE∗3-Leiden mice. PLoS One 2012;7:e49152.
34. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007;6:242-250.
35. Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non- Alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 2012;5:729-733.
36. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592.
37. Lee J, Hong SW, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012;7:e31394.
38. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol 2014;49:481-491.
39. Dentin R, Liu Y, Koo SH, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 2007;449:366-369.
40. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
41. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Ć and hepatic insulin resistance. Cell Metab 2012;15:574-584.
42. Farese RV Jr, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012;15:570-573.
43. Marignani PA, Epand RM, Sebaldt RJ. Acyl chain dependence of diacylglycerol activation of protein kinase C activity in vitro. Biochem Biophys Res Commun 1996;225:469-473.
44. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-689.
45. Magkos F, Su X, Bradley D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012;142:1444-1446 e1442.
46. Renaud HJ, Cui JY, Lu H, Klaassen CD. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liverinsights into mechanisms of hepatic steatosis. PLoS One 2014;9:e88584.
47. Ou J, Tu H, Shan B, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A 2001;98:6027- 6032.
48. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non- Alcoholic fatty liver disease. J Gastroenterol 2013;48:434-441.
49. Higuchi N, Kato M, Tanaka M, et al. Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non- Alcoholic fatty liver disease. Exp Ther Med 2011;2:1077-1081.
50. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010;31:364-395.
51. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675-690.
52. Fletcher JA, Meers GM, Linden MA, et al. Impact of Various Exercise Modalities on Hepatic Mitochondrial Function. Med Sci Sports Exerc 2014;46:1089- 1097.
53. Rebollo A, Roglans N, Baena M, et al. Liquid fructose downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver cells. Biochim Biophys Acta 2014;1841:514-524.
54. Prager GN, Ontko JA. Direct effects of fructose metabolism on fatty acid oxidation in a recombined rat liver mitochondria-hish speed supernatant system. Biochim Biophys Acta 1976;424:386-395.
55. Koves TR, Li P, An J, et al. Peroxisome proliferator- Activated receptorgamma co- Activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 2005;280:33588-33598.
56. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009;139:1073-1081.
57. Arden C, Petrie JL, Tudhope SJ, et al. Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Diabetes 2011;60:3110-3120.
58. Ishimoto T, Lanaspa MA, Rivard CJ, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013;58:1632-1643.
59. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012;287: 40732-40744.